Resources from the same session
LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Presenter: Nancy Lin
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
340O - Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
Presenter: Barbara Pistilli
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA18 and 340O
Presenter: Cristina Saura Manich
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Webcast
LBA19 - Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Presenter: Heather McArthur
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA20 - First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
Presenter: Marleen Kok
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA19 and LBA20
Presenter: Karen Gelmon
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Slides
Webcast